17

Feb2016

Alexion pCPA Negotiation

Suzanne McGurn, the Executive Officer of the Ontario Public Drug Programs, issued a statement on behalf of the Pan Canadian Pharmaceutical Alliance (pCPA), on February 16, 2016 detailing the end of negotiations with manufacturer Alexion for the listing of Soliris. Please see the following article for more information.

12

Feb2016

PMPRB NEW Report: Generics360 – Generic Drugs in Canada, 2014

As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014. Through this newly named report series, the PMPRB monitors and reports on: the latest developments in generic drug pricing and markets ... Read More

12

Feb2016

Modifications to the Procedure for Filing a Drug Submission Application for Generic Drugs with INESSS

Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews. As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ... Read More

25

Nov2015

PDCI Strategic Advice Services for Product Listing Agreements

PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers.  With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ... Read More

03

Nov2015

Presentation and Poll Results from PDCI Market Access Product Listing Agreement (PLA) Webinar is Now Available

On Friday, October 30, 2015 PDCI presented a webinar entitled “Market Access Climate Change: the Evolving Impact of Product Listing Agreements”. The purpose of this webinar was to: Shed light on the recent developments at the pCPA; and Enhance the understanding of the growing practice of PLA negotiations in the private payer ... Read More

20

Oct2015

PDCI Market Access WEBINAR ‒ Market Access Climate Change: the Evolving Impact of Product Listing Agreements

Interested in learning more about new developments at the pan-Canadian Pharmaceutical Alliance (pCPA)? Curious to know more about private payer Product Listing Agreements (PLAs) in Canada? PDCI Market Access (PDCI) is hosting a free webinar on Friday, October 30, 2015 from 11:00 AM -12:00 PM EDT titled Market Access Climate Change: the ... Read More

16

Oct2015

pCPA October Update – Québec officially joins the pCPA & the pCPA Office is now operational

In a recent update released on their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced two significant developments: Québec is now participating in the pCPA; and The Office of the pCPA (the Office) is now operational. In Fall 2014, the Provincial/Territorial Health Ministers announced intentions for Québec’s participation in the Federation’s Health Care ... Read More

23

Feb2015

Pan-Canadian Generics – Centralized Price Confirmation Process

Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve as the single point of entry for the pan-Canadian generic price tier confirmation process. The Saskatchewan Drug Plan will verify that the Tiered Pricing Framework applies to the ... Read More

16

Oct2014

IBM “Pan Canadian Drugs Negotiation Report” Now Available

Pan-Canadian Pharmaceutical Alliance (pCPA) has posted the IBM Report on its website  The much anticipated IBM report (entitled “Pan Canadian Drugs Negotiation Report”) has now been posted on the pCPA website. The objectives of the IBM engagement include: Recommending options for the development of a permanent model that will facilitate negotiations for brand ... Read More